Non-bismuth 사제요법 후에 가장 효과적인 헬리코박터 2차 제균 치료법은 무엇인가? = The Optimal Second-line Rescue Therapy after Failure of Non-bismuth Quadruple Treatments

참고문헌 (Reference)

1 김상균, "한국인 헬리코박터 파일로리 감염의 진단과 치료 임상 진료지침 개정안 2013" 대한소화기학회 62 (62): 3-26, 2013

2 Gisbert JP, "Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure" 23 : 35-44, 2006

3 Kim JS, "Sequential therapy or triple therapy for Helicobacter pylori infection in Asians: systematic review and meta-analysis" 38 : 118-125, 2014

4 김준성, "Sequential Therapy for Helicobacter pylori Infection in Korea: Systematic Review and Meta-Analysis" 거트앤리버 발행위원회 7 (7): 546-551, 2013

5 Graham DY, "Rational Helicobacter pylori therapy:evidence-based medicine rather than medicine-based evidence" 12 : 177-186, 2014

6 Lee JW, "Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012" 18 : 206-214, 2013

7 공은정, "Meta-Analysis of First-Line Triple Therapy for Helicobacter pylori Eradication in Korea: Is It Time to Change?" 대한의학회 29 (29): 704-713, 2014

8 Malfertheiner P, "Management of Helicobacter pylori infection--the Maastricht Iv/ Florence Consensus Report" 61 : 646-664, 2012

9 Gisbert JP, "Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second-line regimen in the presence of levofloxacin resistance-authors' reply" 41 : 1221-1222, 2015

10 Graham DY, "Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second line regimen in the presence of levofloxacin resistance" 41 : 1220-1221, 2015

11 Graham DY, "Helicobacter pylori treatment in the era of increasing antibiotic resistance" 59 : 1143-1153, 2010

12 Gisbert JP, "Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuthcontaining quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments" 41 : 768-775, 2015

13 Kang KK, "Helicobacter pylori eradication with moxifloxacin-containing therapy following failed firstline therapies in South Korea" 20 : 6932-6938, 2014

14 Lee HJ, "Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies" 21 : 351-359, 2015

15 Wagstaff AJ, "Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease" 36 : 132-157, 1988